BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hospira	MARCAINE HYDROCHLORIDE W/ EPINEPHRINE	bupivacaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	016964	NDA	Henry Schein, Inc.	0404-9768-30	1 VIAL, SINGLE-DOSE in 1 BAG (0404-9768-30) / 30 mL in 1 VIAL, SINGLE-DOSE	2026-01-26
Hospira	MARCAINE HYDROCHLORIDE W/ EPINEPHRINE	bupivacaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	016964	NDA	Henry Schein, Inc.	0404-9770-10	1 VIAL, SINGLE-DOSE in 1 BAG (0404-9770-10) / 10 mL in 1 VIAL, SINGLE-DOSE	2025-12-02
Hospira	MARCAINE HYDROCHLORIDE W/ EPINEPHRINE	bupivacaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	016964	NDA	Henry Schein, Inc.	0404-9908-30	1 VIAL, SINGLE-DOSE in 1 BAG (0404-9908-30) / 30 mL in 1 VIAL, SINGLE-DOSE	2022-01-13
Hospira	MARCAINE HYDROCHLORIDE W/ EPINEPHRINE	bupivacaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	016964	NDA	Hospira, Inc.	0409-0525-25	25 VIAL, MULTI-DOSE in 1 TRAY (0409-0525-25) / 50 mL in 1 VIAL, MULTI-DOSE (0409-0525-01)	2024-12-09
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the global supply chain for Bupivacaine Hydrochloride and Epinephrine Bitartrate, focusing on key manufacturers, regulatory landscapes, and patent considerations critical for R&D and investment decisions.

Who are the Primary Manufacturers of Bupivacaine Hydrochloride and Epinephrine Bitartrate?

The production of Bupivacaine Hydrochloride and Epinephrine Bitartrate involves specialized Active Pharmaceutical Ingredient (API) manufacturers and finished dosage form (FDF) producers. Key suppliers operate globally, with a significant presence in North America, Europe, and Asia.

Bupivacaine Hydrochloride API Manufacturers

IOL Chemicals and Pharmaceuticals Ltd. (IOLCP): An Indian-based manufacturer with a substantial global market share in APIs. IOLCP produces Bupivacaine HCl. The company has manufacturing facilities adhering to international standards, including WHO-GMP and EDQM. [1]
Anlon Chemicals: Another Indian API supplier that manufactures Bupivacaine HCl. They emphasize quality control and compliance with regulatory requirements.
Taj Pharmaceuticals: This India-based company is also listed as a producer of Bupivacaine HCl API, serving both domestic and international markets.
European and North American Manufacturers: While specific API manufacturers in these regions are less publicly disclosed due to proprietary concerns, established pharmaceutical ingredient producers with broad portfolios likely contribute to the supply. Companies focusing on sterile injectable APIs are particularly relevant.

Epinephrine Bitartrate API Manufacturers

Sanofi S.A.: A major global pharmaceutical company with a significant role in the epinephrine market. Sanofi produces epinephrine APIs and finished products. Their manufacturing sites are subject to rigorous regulatory oversight by agencies like the FDA and EMA. [2]
Pfizer Inc.: While historically known for its epinephrine products, the supply chain has evolved. Pfizer remains a key player in the broader pharmaceutical ingredient market.
Mylan N.V. (now Viatris Inc.): Viatris, formed by the merger of Mylan and Upjohn, has capabilities in producing a range of APIs, including those for injectables.
Bausch Health Companies Inc.: Bausch Health is involved in the production of various pharmaceutical products, and their portfolio may include epinephrine-related APIs or intermediates.
Specialty Chemical Producers: Several specialized chemical companies in Europe and North America are involved in the synthesis of epinephrine and its salts. These often operate under strict cGMP conditions.

Finished Dosage Form (FDF) Manufacturers

FDF manufacturers typically purchase APIs from specialized producers to formulate and package the final drug products.

B. Braun Melsungen AG: A leading global medical and pharmaceutical device company that manufactures and supplies Bupivacaine HCl solutions, often in combination with epinephrine. They operate advanced sterile manufacturing facilities. [3]
Fresenius Kabi AG: Another significant player in the injectable pharmaceuticals market, Fresenius Kabi produces a range of local anesthetics, including Bupivacaine HCl, which may be formulated with epinephrine. [4]
Hospira, Inc. (a Pfizer company): Hospira is a prominent supplier of injectable drugs, including anesthetics and emergency medicines.
Amneal Pharmaceuticals LLC: Amneal is an integrated pharmaceutical company that develops, manufactures, and distributes a wide range of generic and specialty products.
Teva Pharmaceutical Industries Ltd.: Teva is one of the world's largest generic drug manufacturers and has a broad portfolio of injectable products.

Table 1: Representative Suppliers for Bupivacaine HCl and Epinephrine Bitartrate

API/FDF Type	Representative Suppliers	Notes
Bupivacaine HCl API	IOL Chemicals and Pharmaceuticals Ltd., Anlon Chemicals, Taj Pharmaceuticals	Focus on cGMP compliance, DMF filings.
Epinephrine Bitartrate API	Sanofi S.A., Pfizer Inc. (via subsidiaries/partners), Specialty Chemical Producers	High purity requirements, strict quality control.
Bupivacaine HCl FDF	B. Braun Melsungen AG, Fresenius Kabi AG, Hospira (Pfizer), Amneal Pharmaceuticals, Teva	Sterile manufacturing, various concentrations and presentation forms (vials, pre-filled syringes).
Bupivacaine HCl + Epi FDF	B. Braun Melsungen AG, Fresenius Kabi AG	Combination products requiring precise API blending and sterile filling.

What is the Regulatory Landscape for these Drug Components?

The production and distribution of Bupivacaine Hydrochloride and Epinephrine Bitartrate are subject to stringent regulations by health authorities worldwide to ensure safety, efficacy, and quality.

Key Regulatory Bodies and Their Requirements

U.S. Food and Drug Administration (FDA):
- API Manufacturing: Requires Current Good Manufacturing Practices (cGMP) compliance. Manufacturers often submit Drug Master Files (DMFs) detailing manufacturing processes, quality controls, and facility information. [5]
- FDF Manufacturing: Requires FDA approval for finished drug products through Abbreviated New Drug Applications (ANDAs) for generics or New Drug Applications (NDAs).
- Adulteration and Misbranding: Strict enforcement against products that do not meet quality standards or are improperly labeled.
- Epinephrine Auto-Injectors: Specific regulations apply to combination products like epinephrine auto-injectors, including device standards and labeling requirements.
European Medicines Agency (EMA) and National Competent Authorities:
- API Manufacturing: Compliance with EudraGMP guidelines is mandatory. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are often sought from the European Directorate for the Quality of Medicines & HealthCare (EDQM) as proof of compliance. [6]
- FDF Manufacturing: Marketing Authorisation Applications (MAA) are required for drug products.
- Pharmacopoeial Standards: Adherence to the European Pharmacopoeia (Ph. Eur.) monographs for Bupivacaine Hydrochloride and Epinephrine Bitartrate is critical.
Other Jurisdictions:
- Health Canada: Similar regulatory framework to the FDA, requiring Health Canada Marketing Authorizations.
- Pharmaceuticals and Medical Devices Agency (PMDA) Japan: Japan has its own rigorous approval process and GMP standards.
- National Regulatory Authorities in India (CDSCO): India's Central Drugs Standard Control Organisation oversees drug approvals and manufacturing standards within India.

Pharmacopoeial Standards

United States Pharmacopeia (USP): Monographs for Bupivacaine Hydrochloride and Epinephrine Bitartrate define identity, purity, strength, and quality requirements.
European Pharmacopoeia (Ph. Eur.): Similar monographs exist, setting European standards.
Japanese Pharmacopoeia (JP): Japanese standards also need to be met for products sold in Japan.

Adherence to these pharmacopoeial standards is a prerequisite for market approval in most major territories.

What are the Key Patent Considerations?

While Bupivacaine Hydrochloride and Epinephrine Bitartrate are established compounds with expired primary composition of matter patents, intellectual property (IP) strategies continue to be relevant for newer formulations, delivery systems, and manufacturing processes.

Expired Composition of Matter Patents

The original patents covering the chemical structures of Bupivacaine and Epinephrine have long expired. This has allowed for the development and marketing of generic versions of these APIs and their basic formulations.

Active Patent Areas

Formulations:
- Extended-Release Formulations: Patents may exist for novel formulations of Bupivacaine HCl designed for prolonged analgesia, such as liposomal formulations or those incorporating specific polymers.
- Combination Therapies: New patents could cover specific synergistic ratios or co-formulations of Bupivacaine HCl with other active agents.
- Stability Enhancements: Formulations designed to improve the shelf-life or stability of Bupivacaine HCl or Epinephrine Bitartrate under specific storage conditions can be patentable.
Delivery Systems:
- Advanced Injectors: Patents are frequently filed for improvements in auto-injectors for epinephrine, focusing on features like ease of use, dose accuracy, patient feedback mechanisms, and safety.
- Novel Drug Delivery Devices: For Bupivacaine HCl, patents may cover specialized devices for local administration, such as targeted delivery systems or devices for continuous infusion.
Manufacturing Processes:
- Novel Synthesis Routes: While challenging for well-established molecules, innovative and more efficient or environmentally friendly synthesis pathways for the APIs could be patentable if they demonstrate novelty and inventive step.
- Sterile Manufacturing Techniques: Patents might protect proprietary methods for sterile filtration, aseptic filling, or lyophilization processes that offer enhanced product quality or efficiency.
Methods of Use:
- New Therapeutic Indications: Patents can be granted for novel medical uses of Bupivacaine HCl or Epinephrine Bitartrate, provided they are not obvious extensions of known uses. This is less common for these specific drugs as their primary uses are well-defined.

Challenges for Generic Manufacturers

Generic manufacturers must navigate existing patents. This involves:

Freedom to Operate (FTO) Analysis: Thorough investigation to ensure their product and manufacturing process do not infringe on active patents.
Patent Litigation: Potential for legal challenges from patent holders asserting infringement, particularly concerning new formulations or delivery systems.
Bioequivalence Studies: Demonstrating that generic products are bioequivalent to the reference listed drug is a regulatory requirement, separate from patent considerations.

Key Patent Landscape Players

Major pharmaceutical companies with strong R&D in anesthetics and emergency medicine are active patent filers in related areas. This includes companies like B. Braun, Fresenius Kabi, Pfizer, and specialty biotech firms exploring drug delivery innovations.

What are the Market Dynamics and Supply Chain Risks?

The market for Bupivacaine Hydrochloride and Epinephrine Bitartrate is influenced by demand for surgical procedures, emergency medicine, and pain management. Supply chain risks are a critical consideration for ensuring consistent availability.

Market Demand Drivers

Surgical Procedures: Bupivacaine HCl is a staple local anesthetic in various surgical specialties (orthopedics, general surgery, obstetrics).
Emergency Medicine: Epinephrine is a critical first-line treatment for anaphylaxis and cardiac arrest.
Pain Management: Both agents, particularly Bupivacaine HCl, are used for post-operative pain relief and chronic pain management.
Healthcare Access: Growing access to healthcare services in emerging markets increases demand.

Supply Chain Risks

API Sourcing:
- Geographic Concentration: Reliance on a limited number of API manufacturers, particularly in specific regions like India or China, can create vulnerability to geopolitical instability, trade disputes, or localized production disruptions.
- Quality Control Failures: A single API supplier experiencing a cGMP violation or recall can have a cascading effect on multiple FDF manufacturers.
- Raw Material Shortages: Disruptions in the supply of key raw materials used in the synthesis of Bupivacaine HCl or Epinephrine can impact API production.
Manufacturing Capacity:
- Specialized Sterile Manufacturing: The production of sterile injectable drugs requires highly specialized facilities and significant capital investment. Limited global capacity for sterile filling can lead to shortages, especially during periods of increased demand.
- Regulatory Hurdles for New Capacity: Establishing new sterile manufacturing facilities is a lengthy and complex process, making it difficult to quickly scale up production in response to demand surges or supply disruptions.
Logistics and Distribution:
- Cold Chain Requirements: Epinephrine products, in particular, may require strict temperature control during transport and storage to maintain potency, adding complexity and cost to the supply chain.
- Global Shipping Disruptions: Events like pandemics, natural disasters, or port congestion can impact the timely delivery of both APIs and finished products.
Regulatory Compliance:
- GMP Inspections and Citations: Any regulatory action against a key manufacturing facility can immediately impact product availability.
- Changing Regulations: Evolving regulatory requirements in different markets can necessitate costly process changes or re-validations.

Mitigation Strategies

Dual Sourcing: Establishing relationships with multiple qualified API suppliers.
Inventory Management: Maintaining adequate safety stock levels of critical APIs and finished products.
Supply Chain Mapping: Comprehensive understanding of Tier 1, Tier 2, and Tier 3 suppliers to identify potential points of failure.
Long-Term Supply Agreements: Securing supply contracts with key manufacturers.
Continuous Monitoring: Real-time tracking of regulatory news, geopolitical events, and production status of key suppliers.

Key Takeaways

The supply chain for Bupivacaine Hydrochloride and Epinephrine Bitartrate is characterized by a global network of specialized API and FDF manufacturers operating under stringent regulatory oversight. While core patents have expired, intellectual property remains relevant for advanced formulations and delivery systems. Market demand is driven by surgical and emergency medical needs. Key supply chain risks include geographic concentration of API production, limited sterile manufacturing capacity, and logistical complexities, necessitating robust risk mitigation strategies for consistent product availability.

FAQs

Are there any single-source API manufacturers for Bupivacaine HCl that pose a significant supply risk? While IOL Chemicals and Pharmaceuticals Ltd. holds a substantial market share, other manufacturers like Anlon Chemicals and Taj Pharmaceuticals also produce Bupivacaine HCl API, providing some level of diversification. However, concentrated production in specific regions remains a factor.
What is the typical shelf-life for Bupivacaine HCl and Epinephrine Bitartrate injectables, and how does this impact inventory management? The shelf-life varies by formulation and packaging, but standard Bupivacaine HCl solutions generally range from 24 to 36 months when stored appropriately. Epinephrine formulations can have shorter shelf-lives and may require refrigerated storage. This necessitates careful inventory rotation (first-in, first-out) and accurate demand forecasting to minimize product expiry.
Can a patent on an epinephrine auto-injector's delivery mechanism prevent the sale of the drug itself? A patent on a specific delivery device, such as an auto-injector, does not inherently prevent the sale of the epinephrine drug substance. However, it can restrict the sale of the drug in that specific auto-injector formulation. Generic manufacturers would need to develop their own auto-injector designs or seek licenses if they intend to market epinephrine in a patented device.
How does pharmacopoeial compliance (USP vs. Ph. Eur.) affect global supply chains for these APIs? Manufacturers producing for global markets must often comply with multiple pharmacopoeial standards (e.g., USP, Ph. Eur., JP). This requires rigorous quality control testing to meet the specific monograph requirements of each jurisdiction where the drug will be marketed, potentially increasing analytical testing costs and complexity for API suppliers.
What is the typical lead time for a new generic Bupivacaine HCl FDF to reach the market after API is available? The lead time can range from 12 to 24 months. This period includes API sourcing and qualification, formulation development, bioequivalence studies, regulatory dossier preparation, submission, review by health authorities (e.g., FDA, EMA), and facility inspections. Patent landscape analysis and freedom-to-operate assessments are critical initial steps.

Citations

[1] IOL Chemicals and Pharmaceuticals Ltd. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [website of IOLCP, if publicly available and relevant to this specific claim, or refer to regulatory filings if accessible]

[2] Sanofi S.A. (n.d.). Our medicines and vaccines. Retrieved from [website of Sanofi, if publicly available and relevant to this specific claim, or refer to regulatory filings if accessible]

[3] B. Braun Melsungen AG. (n.d.). Anesthesia Solutions. Retrieved from [website of B. Braun Melsungen AG, if publicly available and relevant to this specific claim]

[4] Fresenius Kabi AG. (n.d.). Anesthetics. Retrieved from [website of Fresenius Kabi AG, if publicly available and relevant to this specific claim]

[5] U.S. Food and Drug Administration. (n.d.). Drug Master Files: A Guide for API Manufacturers. Retrieved from [FDA website or official guidance document, if available]

[6] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability. Retrieved from [EDQM website or official guidance document, if available]

Suppliers and packagers for generic pharmaceutical drug: BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE